Literature DB >> 26648657

Apremilast.

.   

Abstract

Year:  2015        PMID： 26648657      PMCID： PMC4657300          DOI： 10.18773/austprescr.2015.064

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  4 in total

1.  Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Authors:  Kim Papp; Jennifer C Cather; Les Rosoph; Howard Sofen; Richard G Langley; Robert T Matheson; ChiaChi Hu; Robert M Day
Journal:  Lancet       Date:  2012-06-29       Impact factor: 79.321

2.  Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Marla Hochfeld; Lichen L Teng; Georg Schett; Eric Lespessailles; Stephen Hall
Journal:  J Rheumatol       Date:  2015-01-15       Impact factor: 4.666

3.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

Authors:  Kim Papp; Kristian Reich; Craig L Leonardi; Leon Kircik; Sergio Chimenti; Richard G B Langley; ChiaChi Hu; Randall M Stevens; Robert M Day; Kenneth B Gordon; Neil J Korman; Christopher E M Griffiths
Journal:  J Am Acad Dermatol       Date:  2015-07       Impact factor: 11.527

4.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal:  Ann Rheum Dis       Date:  2014-03-04       Impact factor: 19.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.